Effects of Conventional and Ozonated Autohemotherapy as Adjuvant Treatment in Dogs with Transmissible Venereal Tumor (TVT)

Transmissible venereal tumor (TVT) is a contagious neoplasm affecting dogs, commonly treated with vincristine sulfate, although this protocol may be associated with adverse effects and the need for multiple therapeutic sessions. In this context, adjuvant therapies have been investigated to optimize clinical outcomes. This study evaluated the effect of conventional and ozonated autohemotherapy on the number of chemotherapy sessions required to achieve complete remission of TVT. Fifteen dogs with a confirmed diagnosis were randomly allocated into three groups: control (vincristine, n = 5), conventional autohemotherapy associated with vincristine (AHTm, n = 5), and ozonated autohemotherapy associated with vincristine (AHTmO3, n = 5). The animals were evaluated weekly through clinical, cytological, hematological, and biochemical examinations. The primary outcome was the number of sessions required to achieve complete remission. A significant reduction was observed in the AHTm (p = 0.032) and AHTmO3 (p = 0.008) groups compared to the control group. No differences were found in laboratory parameters. The findings suggest that autohemotherapy, particularly in its ozonated form, may serve as a promising adjuvant strategy. However, studies with larger sample sizes are needed.